Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 843 results for "gilead sciences"

Morgan Stanley Reiterates Hold Rating for Gilead Sciences, Inc. (GILD)
American Banking News - Earnings

Morgan Stanley Reiterates Hold Rating for Gilead Sciences, Inc...

Gilead Sciences, Inc. (NASDAQ:GILD)s stock had its hold rating reiterated by stock analysts at Morgan Stanley in a report issued on Sunday. In related news, CEO John F. Milligan sold 112,000 shares of the company's stock in a transaction dated ... American Banking News - Earnings, 12 hours ago

116 images for gilead sciences

American Banking News, 12 hours ago
Bidness Etc, 3 days ago
Bidness Etc, 5 days ago
Bidness Etc, 1 week ago
Jutia Group, 2 days ago
Bidness Etc, 1 week ago
Nasdaq, 3 days ago, 1 week ago, 1 week ago
Motley Fool, 5 days ago
Seeking Alpha

How Much More Time Will Investors Give Gilead?

One cannot blame shareholders for becoming quite impatient with the management of Gilead Sciences (NASDAQ: GILD ) in 2016. The stock has done nothing for the past 18 months even though earnings per share sextupled from FY2013 through FY2015.
 Seeking Alpha3 hours ago

Gilead Gets European CHMP's Positive Opinion For Epclusa For All Genotypes of Chronic Hepatitis C Treatment

Gilead Sciences, Inc. (NASDAQ: GILD ) revealed that the Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency's (EMA) Scientific Committee, has adopted a positive opinion on its Marketing Authorization Application (MAA) ...
 Benzinga.com3 days ago EMA panel recommends approval of Epclusa for all HCV genotypes  Healio3 days ago Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 10  Pharmacy Choice3 days ago European Ad Comm backs Gilead's once-daily pan-genotypic HCV pill Epclusa  Seeking Alpha3 days ago
Bidness Etc

Celgene, Gilead Added to Medivation Suitor List

Biotech companies Celgene Corp. and Gilead Sciences Inc. could be considering bids for Medivation Inc., in addition to Sanofi, according to a Bloomberg article. As reported last month, Sanofi remains the most serious bidder, with their unsolicited, ...
 Pharmaceutical Manufacturing Magazine5 days ago Medivation Inc M&A: Plot Thickens With Possible Entry Of Gilead, Celgene  Bidness Etc3 days ago Count Celgene and Gilead as New Suitors to Acquire the Popular Medivation  BioSpace5 days ago Celgene, Gilead Said to Join Suitors Mulling Medivation Bids  Bloomberg5 days ago

EU regulators recommend approving Gilead's new hepatitis C drug

May 27 (Reuters) - Gilead Sciences Inc's new hepatitis C drug combination, which shares an active ingredient with blockbuster Sovaldi, was recommended for marketing approval by the European Medicines Agency. The EMA's Committee for Medicinal ...
 Yahoo! Finance3 days ago Gilead Sciences : Patent Issued for Apoptosis Signal-Regulating Kinase Inhibitor (USPTO 9333197)  4 Traders1 week ago India Patent Office approves Gilead's hepatitis C drug patent  Reuters2 weeks ago Patent not to affect hepatitis C drug price in India: Gilead  Business Standard2 weeks ago

EU regulators back approval of Gilead's new hep C drug

An advisory panel to the European drug regulator recommended an approval for Gilead Sciences Inc's new drug combination to treat hepatitis C. The European Medicines Agency (EMA) said on Friday that the Committee for Medicinal Products for Human ...
 Pharmaceutical Tech.com2 days ago UPDATE 1-EU regulators back approval of Gileads new hep C drug  Reuters UK3 days ago Gilead's HIV drug gets closer to getting Europe approval  HealthMediciNet.com1 week ago Infection worries prompt EU review of Gilead leukemia drug  Reuters2 months ago

Three more pharma giants subpoenaed in charity investigation

Dive Brief: Gilead Sciences, Biogen Inc. and Jazz Pharmaceuticals have been subpoenaed in a federal investigation into the relationship between pharmaceutical companies and nonprofits that help patients afford prescription drugs, Bloomberg News ...
 BioPharma Dive3 days ago Feds ask Gilead, Biogen, Jazz for info on ties to charities  FiercePharma3 days ago Gilead, Biogen, Jazz Pharma Subpoenaed as Feds Investigate Drugmaker-Charity Connections  BioSpace3 days ago Gilead Subpoenaed as Feds Probe Drugmaker-Charity Connections  Bloomberg3 days ago

Don't Count Out Gilead's Oncology Portfolio Just Yet

A great heap of analysis has been spent on Gilead Sciences (NASDAQ: GILD ) following its numerous pieces of bad news in 2016. Perhaps most notably was the stoppage of six trials containing its flagship leukemia drug idelalisib on the basis of ...
 Seeking Alpha3 days ago
Bidness Etc

Gilead Sciences -- Strong Buy Despite Management Shakeup: Barrons

This decision to bring about a management shake-up comes at a point of relative weakness for the company, but points towards new horizons moving forward Gilead Sciences, Inc. ( NASDAQ:GILD ) is bringing a complete turnaround to its executive ...
 Bidness Etc3 days ago
Motley Fool

Better Buy: Gilead Sciences Inc. vs. Johnson & Johnson

Image source: Johnson & Johnson. They're two of the biggies in healthcare. Gilead Sciences Inc. ( NASDAQ:GILD ) grew to become the largest biotech in the world over the last decade on the back of its HIV and hepatitis C franchises. Meanwhile, ...
 Motley Fool4 days ago Johnson & Johnson Issues Call for Innovative Ideas to Reduce HIV Infections in Sub-Saharan Africa  National AIDS Treatment Advocacy Project4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
Get updated on latest news & your favorite topics right in your inbox!
More     Less